Pharmas restock pipelines amid rise in FDA approvals; Watson inks pact to market experimental overactive bladder treatment;

@FierceBiotech: Pfizer's potential offload of biz units could aid R&D prospects. Article | Follow @FierceBiotech

> Watson Pharmaceuticals has shelled out an undisclosed sum to sell Antares Pharma's experimental treatment for overactive bladder in the U.S. and Canada. Report

> TheStreet's Adam Feuerstein writes about the odds that developer Oncothyreon's ($ONTY) will succeed with its late-stage trial of a cancer immunotherapy Stimuvax in lung cancer patients. Item

> Alnylam Pharmacueticals, a developer of gene-silencing drugs calls RNAi therapeutics, has asked regulators for permission to begin a Phase I clinical trial of its drug ALN-PCS for severe hypercholesterolemia. The firm hopes to begin the trial by the end of this year. Release

> Acura Pharmaceuticals has appointed Robert B. Jones as its new president and CEO, replacing Andy Reddick, who passed away on April 28. Jones has been in the position on an interim basis since Reddick's death. Story

> Biogen Idec ($BIIB) vet Andrew Hirsch has joined Waltham, MA-based biotech startup Avila Therapeutics as the firm's first chief financial officer. Release

Pharma News

@FiercePharma: Nine of 10 Big Pharmas cut sales reps in 2010. Report | Follow @FiercePharma

> Valeant snaps up Sanofi's Dermik for $425M. News

> Bayer's Yasmin to face EU generics this year. Story

> Pfizer bids for $770M Lipitor extension in EU. Item

Biotech IT News

> Two computational biology standouts honored. Report

> IBM cloud aids fight against superbugs. Story

> Health informatics giant Optum changes CEOs. Article

> Sequencing giant BGI advances in bioinformatics game. Report

> BioTox buys CRO Bio-Quant, eyes software integration. Story

> Biomolecular computer shows promise in detecting disease. Article

Medical Device News

> FDA may change premarket notification requirements for radiology devices. Report

> SurgiQuest closes $19M round. Piece

> QIAGEN amends offer for Cellestis, provides update on Ipsogen. News

> BD gets partial win in patent case. Story

> Medtronic advises doctors of pump problem. Article

> Medtronic buys two surgical products companies. Report

And Finally... The Wall Street Journal reports that, amid a jump in FDA approvals of new drugs this year, pharmas are restocking their pipelines. Article

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.